Pemetrexed Induced Life-threatening Anaphylaxis.
Publication/Presentation Date
8-29-2019
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Society for Clinical Oncology (ASCO) recommends platinum based regimens as the first-line of treatment for NSCLC. Pemetrexed, an antifolate agent, has been approved by the ASCO for the treatment of advanced non-squamous NSCLC and has been shown to be efficient for first-line, maintenance and second- or third-line treatment in this subgroup. It is administered intravenously over 10 minutes and is usually well tolerated with a very few side effects. There have been a few cases of anaphylaxis reported with pemetrexed use and most of the patients presented only with cutaneous manifestations. We present a patient with stage IV adenocarcinoma of the lung who developed a severe life threatening anaphylactic reaction requiring ventilatory support after administration of pemetrexed.
Volume
11
Issue
8
First Page
5514
Last Page
5514
ISSN
2168-8184
Published In/Presented At
Rajasurya, V., Pyakuryal, B., Gunasekaran, K., Sekar, V., & Dhakal, P. (2019). Pemetrexed Induced Life-threatening Anaphylaxis. Cureus, 11(8), e5514. https://doi.org/10.7759/cureus.5514
Disciplines
Medicine and Health Sciences
PubMedID
31687290
Department(s)
Department of Medicine, Hematology-Medical Oncology Division Fellows and Residents, Fellows and Residents
Document Type
Article